MGTX
Data day is almost here
MeiraGTx is set to host a conference call and webcast on Thursday morning to walk through 3-year follow-up data from its Phase 1 AQUAx study of AAV-hAQP1. That’s the company’s gene therapy for radiation-induced xerostomia, which is the delightfully un-fun medical term for dry mouth after radiation treatment.
Why investors are watching
This is the kind of moment biotech investors live for: a fresh data readout that could either add rocket fuel to the stock or turn the mood into a group chat full of sad-face emojis. Long-term follow-up matters here because early-stage gene therapy stories can sound amazing right up until durability and safety show up to the party.
The setup behind the hype
MeiraGTx already has momentum heading into the presentation, with shares riding near their 52-week high after a big run over the past year. The company also recently picked up FDA Breakthrough Therapy Designation for AAV2-hAQP1, which gave the story extra shine and helped pull in more bullish analyst commentary.
Big picture
If the 3-year data looks solid, MeiraGTx gets a stronger case that this isn’t just a flashy science project. If not, investors may have to reprice the “gene therapy for dry mouth” narrative a little less romantically.